老年晚期非小细胞肺癌患者的治疗

摘要/Abstract

摘要：化疗通常被推荐用于ⅢB/Ⅳ期非小细胞肺癌(NSCLC)的治疗，老年晚期NSCLC患者的治疗方案主要为单药化疗以及以铂类为基础的联合化疗。但是老年患者由于年龄相关的一些疾病导致化疗耐受性差，因此疗效相对于年轻患者差。靶向治疗及免疫治疗成为新的研究方向。根据老年患者特点（老年状态评分系统）选择合适的方案十分重要。

关键词:癌,非小细胞肺,老年人,肿瘤治疗方案

Abstract:Chemotherapy is recommended for stage ⅢB/Ⅳ nonsmall cell lung cancer (NSCLC) treatment. The treatments for elderly patients with advanced NSCLC are mainly singleagent chemotherapy and platinumbased combination chemotherapy. However, elderly patients tolerate chemotherapy poorly because of agerelated comorbidities. Therefore, the curative effect of elderly patients is relatively poorer as compared to their younger counterparts. Targeted therapy and immune therapy have become new research directions. It is important to select an appropriate program for elderly patients according to geriatric assessments.

Key words:Carcinoma, non-small-cell lung,Aged,Antineoplastic protocols

周金，武杰，张惠博，陈敏. 老年晚期非小细胞肺癌患者的治疗[J]. 国际肿瘤学杂志, 2018, 45(12): 756-759.

Zhou Jin, Wu Jie, Zhang Huibo, Chen Min. Therapy for elderly patients with advanced nonsmall cell lung cancer[J]. Journal of International Oncology, 2018, 45(12): 756-759.

参考文献

［1］ Davidoff AJ, Tang M, Seal B, et al. Chemotherapy and survival benefit in elderly patients with advanced nonsmallcell lung cancer［J］. J Clin Oncol, 2010, 28(13): 21912197. DOI: 10.1200/JCO.2009.25.4052. ［2］ Santos FN, Cruz MR, Riera R, et al. Chemotherapy for advanced nonsmallcell lung cancer in elderly patients［J］. JAMA Oncol, 2016, 2(12): 16451646. DOI: 10.1001/jamaoncol.2016.2050. ［3］ Santos FN, de Castria TB, Cruz MR, et al. Chemotherapy for advanced nonsmall cell lung cancer in the elderly population［J］. Cochrane Database Syst Rev, 2015(10): CD010463. DOI: 10.1002/14651858.CD010463.pub2. ［4］ Gridelli C, Morabito A, Cavanna L, et al. Cisplatinbased firstline treatment of elderly patients with advanced nonsmallcell lung cancer: joint analysis of MILES3 and MILES4 Phase Ⅲ Trials［J］. J Clin Oncol, 2018, 36(25): 25852592. DOI: 10.1200/JCO.2017.76.8390. ［5］ Presley CJ, Reynolds CH, Langer CJ. Caring for the older population with advanced lung cancer［J］. Am Soc Clin Oncol Educ Book, 2017, 37: 587596. DOI: 10.14694/edbk_179850. ［6］ Gridelli C, Brodowicz T, Langer CJ, et al. Pemetrexed therapy in elderly patients with good performance status: analysis of two phase Ⅲ trials of patients with nonsquamous nonsmallcell lung cancer［J］. Clin Lung Cancer, 2012, 13(5): 340346. DOI: 10.1016/j.cllc.2011.12.002. ［7］ PazAres LG, Zimmermann A, Ciuleanu T, et al. Metaanalysis examining impact of age on overall survival with pemetrexed for the treatment of advanced nonsquamous nonsmall cell lung cancer［J］. Lung Cancer, 2017, 104: 4551. DOI: 10.1016/j.lungcan.2016.12.007. ［8］ Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nabpaclitaxel in combination with carboplatin versus solventbased paclitaxel plus carboplatin as firstline therapy in patients with advanced nonsmallcell lung cancer: final results of a phase Ⅲ trial［J］. J Clin Oncol, 2012, 30(17): 20552062. DOI: 10.1200/jco.2011.39.5848. ［9］ Reck M, Von Pawel J, Zatloukalet P, et al. Overall survival with cisplatingemcitabine and bevacizumab or placebo as firstline therapy for nonsquamous nonsmallcell lung cancer: resultsfrom a randomised phase Ⅲ trial［J］. Ann Oncol, 2010, 21(9): 18041809. DOI: 10.1093/annonc/mdq020. ［10］ Leighl NB, Zatloukal P, Mezger J, et al. Efficacy and safety of bevacizumabbased therapy in elderly patients with advanced or recurrent nonsquamous nonsmall cell lung cancer in the phase Ⅲ BO17704 study (AVAiL)［J］. J Thorac Oncol, 2010, 5(12): 19701976. DOI: 10.1097/JTO.0b013e3181f49c22. ［11］ Langer CJ, Socinski MA, Patel JD, et al. Isolating the role of bevacizumab in elderly patients with previously untreated nonsquamous nonsmall cell lung cancer: secondary analyses of the ECOG 4599 and PointBreak Trials［J］. Am J ClinOncol, 2016, 39(5): 441447. DOI: 10.1097/coc.0000000000000163. ［12］ Tian RH, Wu X, Liu X, et al. The role of angiogenesis inhibitors in the treatment of elderly patients with advanced nonsmallcell lung cancer: a metaanalysis of eleven randomized controlled trials［J］. J Cancer Res Ther, 2016, 12(2): 571575. DOI: 10.4103/09731482.151950. ［13］ Gajra A, Jatoi A. Nonsmallcell lung cancer in elderly patients: a discussion of treatment options［J］. J Clin Oncol, 2014, 32(24): 25622569. DOI: 10.1200/jco.2014.55.3099. ［14］ Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutationpositive nonsmallcell lung cancer (EURTAC): a multicentre, openlabel, randomised phase 3 trial［J］. Lancet Oncol, 2012, 13(3): 239246. DOI: 10.1016/s14702045(11)70393x. ［15］ Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for firstline treatment of Asian patients with advanced nonsmallcell lung cancer harbouring EGFR mutations (LUXLung 6): an openlabel, randomised phase 3 trial［J］. Lancet Oncol, 2014, 15(2): 213222. DOI: 10.1016/s14702045(13)706041. ［16］ Tanaka H, Taima K, Tanaka Y, et al. A phase Ⅰ study of afatinib for patients aged 75 or older with advanced nonsmall cell lung cancer harboring EGFR mutations［J］. Med Oncol, 2018, 35(3): 34. DOI: 10.1007/s1203201810983. ［17］ Morikawa N, Minegishi Y, Inoue A, et al. Firstline gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of NorthEast Japan Study Group studies［J］. Expert Opin Pharmacother, 2015, 16(4): 465472. DOI: 10.1517/14656566.2015.1002396. ［18］ Corre R, Gervais R, Guisier F, et al. Octogenarians with EGFRmutated nonsmall cell lung cancer treated by tyrosinekinase inhibitor: a multicentric realworld study assessing tolerance and efficacy (OCTOMUT study)［J］. Oncotarget, 2018, 9(9): 82538262. DOI: 10.18632/oncotarget.23836. ［19］ Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFRmutated advanced nonsmallcell lung cancer［J］. N Engl J Med, 2018, 378(2): 113125. DOI: 10.1056/NEJMoa1713137. ［20］ Soria JC, Tan DSW, Chiari R, et al. Firstline ceritinib versus platinumbased chemotherapy in advanced ALKrearranged nonsmallcell lung cancer (ASCEND4): a randomised, openlabel, phase 3 study［J］. Lancet, 2017, 389(10072): 917929. DOI: 10.1016/s01406736(17)30123x. ［21］ Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALKpositive nonsmallcell lung cancer (JALEX): an openlabel, randomised phase 3 trial［J］. Lancet, 2017, 390(10089): 2939. DOI: 10.1016/s01406736(17)305652. ［22］ Gandhi L, RodriguezAbreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic nonsmallcell lung cancer［J］. N Engl J Med, 2018, 378(22): 20782092. DOI: 10.1056/NEJMoa1801005. ［23］ Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden［J］. N Engl J Med, 2018, 378(22): 20932104. DOI: 10.1056/NEJMoa1801946. ［24］ Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage Ⅲ nonsmallcell lung cancer［J］. N Engl J Med, 2017, 377(20): 19191929. DOI: 10.1056/NEJMoa1709937. ［25］ Gettinger S, Horn L, Jackman D, et al. Fiveyear followup of nivolumab in previously treated advanced nonsmallcell lung cancer: results from the CA209003 study［J］. J Clin Oncol, 2018, 36(17): 16751684. DOI: 10.1200/jco.2017.77.0412. ［26］ Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as firstline treatment for advanced nonsmallcell lung cancer (CheckMate 012): results of an openlabel, phase 1, multicohort study［J］. Lancet Oncol, 2017, 18(1): 3141. DOI: 10.1016/s14702045(16)306246. ［27］ AbdelWahab N, Shah M, LopezOlivo MA, et al. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review［J］. Ann Intern Med, 2018, 168(2): 121130. DOI: 10.7326/m172073. ［28］ NikolichZugich J. The twilight of immunity: emerging concepts in aging of the immune system［J］. Nat Immunol, 2018, 19(1): 1019. DOI: 10.1038/s415900170006x. ［29］ Borghaei H, PazAres L, Horn L, et al. Nivolumab versus docetaxel in sdvanced nonsquamous nonsmallcell lung cancer［J］. N Engl J Med, 2015, 373(17): 16271639. DOI: 10.1056/NEJMoa1507643. ［30］ Reck M, RodriguezAbreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PDL1positive nonsmallcell lung cancer［J］. N Engl J Med, 2016, 375(19): 18231833. DOI: 10.1056/NEJMoa1606774. ［31］ Levy MH, Smith T, AlvarezPerez A, et al. Palliative care, Version 1.2014. Featured updates to the NCCN Guidelines［J］. J Natl Compr Canc Netw, 2014, 12(10): 13791388. ［32］ Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic nonsmallcell lung cancer［J］. N Engl J Med, 2010, 363(8): 733742. DOI: 10.1056/NEJMoa1000678. ［33］ Vergnenegre A, Hominal S, Tchalla AE, et al. Assessment of palliative care for advanced nonsmallcell lung cancer in France: a prospectiveobservational multicenter study (GFPC 0804 study)［J］. Lung Cancer, 2013, 82(2): 353357. DOI: 10.1016/j.lungcan.2013.07.014.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[4]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华.炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[5]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[6]	顾芳萌, 徐晨阳, 雷大鹏.人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[7]	张文馨, 夏泠, 彭晋, 周福祥.甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[8]	王昆, 周中新, 臧其威.血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[9]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇.信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[10]	姚益新, 沈煜霖.血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[11]	胡婷婷, 王越华.电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[12]	王子豪, 王宇, 杨鑫, 何艺, 莫兴奎, 袁涛.铁死亡在骨肉瘤中的分子机制及相关治疗的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 239-244.
[13]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛.索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[14]	严爱婷, 王翠竹, 刘春桂, 鲁小敏.卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[15]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好.基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.